Ovidrel

Ovidrel is a brand name of chorionic gonadotropin (hcg), approved by the FDA in the following formulation(s):

OVIDREL (choriogonadotropin alfa - injectable; subcutaneous)

• 
  Manufacturer: EMD SERONO
  
  Approval date: October 6, 2003
  
  Strength(s): EQ 0.25MG /0.5ML ^[RLD]

Has a generic version of Ovidrel been approved?

No. There is currently no therapeutically equivalent version of Ovidrel available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ovidrel. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Recombinant heterodimeric human fertility hormones, and methods, cells, and vectors and DNA for the production thereof
  Patent 5,767,251
  Issued: June 16, 1998
  Inventor(s): Reddy; Vermuri B. & Hsiung; Nancy & Beck; Anton K. & Bernstine; Edward George
  Assignee(s): Genzyme Corporation
  Biologically active heterodimeric human fertility hormones composed of two different subunits, each subunit being synthesized in the same cell transformed by at least one cell expression vector having heterologous DNA encoding each subunit with each subunit being controlled by a separate promoter. Preferred human fertility hormones include hCG, hLH and hFSH.
  
  Patent expiration dates:
  
  
  • June 16, 2015
    
  
  
  
  • June 16, 2015
    
    ✓ 
    Drug substance
  
  



• 
  HCG liquid formulations
  Patent 6,706,681
  Issued: March 16, 2004
  Inventor(s): Fabrizio; Samaritani & Patrizia; Natale
  Assignee(s): Applied Research System ARS Holding N.V.
  The invention refers to liquid pharmaceutical compositions containing hCG stabilised with a polyalcohol or a non-reducing sugar. Preferably, the compositions are stabilised with mannitol. In the preferred embodiments such compositions are aqueous solutions in a phosphate buffer at pH 7. Such compositions are ready to be injected and, therefore, the step of reconstitution of the lyophilised powder is avoided, thus simplifying the way of use.
  
  Patent expiration dates:
  
  
  • March 16, 2021
    
    ✓ 
    Drug product
  
  

See also...

• Ovidrel Consumer Information (Wolters Kluwer)
• Ovidrel injectable Consumer Information (Cerner Multum)
• Ovidrel Advanced Consumer Information (Micromedex)
• Ovidrel AHFS DI Monographs (ASHP)
• Choriogonadotropin Alfa Consumer Information (Wolters Kluwer)
• Human chorionic gonadotropin (HCG) injectable Consumer Information (Cerner Multum)
• Choriogonadotropin Alfa AHFS DI Monographs (ASHP)
• Gonadotropin, Chorionic AHFS DI Monographs (ASHP)